Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)							3 Months Ended	6 Months Ended
	Mar. 19, 2021	Jan. 25, 2021	Jul. 24, 2020	Apr. 30, 2020	Mar. 18, 2020	Nov. 09, 2018	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Organization Consolidation and Presentation of Financial Statement [Line Items]
Accumulated deficit							$ 103,876,405	$ 103,876,405		$ 99,135,961
Cash and cash equivalents							22,128,332	22,128,332		5,761,568
Net cash used in operating activities								9,242,939	$ (8,700,353)
Proceeds from issuance of common stock, net of issuance costs								3,139,047	$ 1,941,095
Reimbursement payment	$ 14,000,000.0
Development payments	10,000,000.0
Current liabilities							32,207,156	32,207,156		$ 6,145,546
Deferred collaboration funding							19,251,394	19,251,394
Liability related to securities class action and stockholder derivative actions settlements and legal costs							$ 9,400,000	$ 9,400,000
Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock							0	200,000
Issuance of common stock, price per share							$ 2.47	$ 2.47
Proceeds from issuance of common stock gross								$ 500,000
Proceeds from issuance of common stock, net of issuance costs								500,000
Remaining obligation							$ 12,100,000	12,100,000
Number of shares, company may sell on any single business day				50,000
Maximum amount of Common stock at time of sale, per regular purchase				$ 1,000,000.0
Issuance of common stock for commitment fee, shares				148,148
Fair value of the commitment fee shares, recorded to general and administrative expense along with other costs				$ 400,000
Cost, Product and Service [Extensible List]				General and Administrative
Stock to be issued value on certain limitation and condition				$ 12,100,000
Collaboration Agreement | Relief
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received		$ 1,000,000.0
Reimbursement payment	14,000,000.0	14,000,000.0
Guarantee for substantive review food and drug application		0
Milestone payment to be received	6,000,000.0	6,000,000.0
Collaboration Agreement | Relief | First Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments subject new drug application							$ 10,000,000.0
Collaboration Agreement | Relief | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments subject new drug application	$ 10,000,000.0	10,000,000.0						$ 10,000,000.0
Weighted Average | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, price per share							$ 2.47	$ 2.47
Maximum | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Shares value might be issued under agreement				$ 15,000,000.0
Number of shares, company may sell on any single business day				100,000
Maximum | Collaboration Agreement | Relief
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments		$ 20,000,000.0
At-the-Market Facility
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock							0	877,107
Proceeds from issuance of common stock gross								$ 2,800,000
Common stock offering costs								200,000
Proceeds from issuance of common stock, net of issuance costs								$ 2,600,000
At-the-Market Facility | Weighted Average
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, price per share							$ 3.1692	$ 3.1692
At-the-Market Facility | Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Aggregate offering price of common stock					$ 50,000,000.0	$ 50,000,000.0
Private Placement | Directors, Officers and Employees
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock			244,998
Issuance of common stock, price per share			$ 3.50
Proceeds from issuance of common stock, net of issuance costs			$ 900,000